Eyenovia重组债务，包含炒作令牌并导航一个动荡的市场，旨在用数字资产彻底改变眼科技术。

Eyenovia's Bold Bet: Debt Restructuring, HYPE Tokens, and a Digital Future

Eyenovia的大胆下注：债务重组，炒作令牌和数字未来

Eyenovia (NASDAQ:EYEN) is making waves by strategically intertwining ophthalmic technology with the volatile world of digital assets, particularly HYPE tokens. With recent debt restructuring and a foray into cryptocurrency, the company is charting a unique course, though not without its challenges.

Eyenovia（NASDAQ：EYEN）通过战略性地将眼科技术与数字资产的动荡世界（尤其是炒作代币）相结合而引起波浪。随着最近的债务重组和对加密货币的尝试，该公司正在绘制独特的课程，尽管并非没有挑战。

Debt Restructuring: A Lifeline for Eyenovia

债务重组：Eyenovia的生命线

In a significant move, Eyenovia has successfully amended its senior secured debt with Avenue Capital Group. The maturity date has been extended to July 2028 from November 2025, and the interest rate has been reduced from 12% to 8%. This financial restructuring provides crucial breathing room, especially considering Eyenovia's liquidity challenges, as indicated by its current ratio of 0.34. The amended terms allow for interest-only payments for the first 18 months, offering flexibility during a critical phase.

一项重大行动，Eyenovia已成功地修改了Avenue Capital Group的高级担保债务。从2025年11月开始，到期日期已延长至2028年7月，利率已从12％降低到8％。这种财务重组提供了至关重要的呼吸室，尤其是考虑到Eyenovia的流动性挑战，如当前比率为0.34。经修订的条款允许在前18个月内支付仅利息，从而在关键阶段提供了灵活性。

Diving into Digital Assets: The HYPE Token Strategy

潜入数字资产：炒作令牌策略

Eyenovia is making headlines as the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid blockchain. This bold move includes a $50 million private placement to acquire over 1 million HYPE tokens. The company aims to become a leading validator for the Hyperliquid blockchain, positioning itself at the intersection of ophthalmic technology and digital assets.

Eyenovia成为第一家公开上市的美国公司，建立了炒作战略国库，这是超流利区块链的原住民代币。这一大胆的举动包括一个耗资5000万美元的私人安置，以获取超过100万个炒作令牌。该公司的目标是成为超流动区块链的领先验证者，将自己定位在眼科技术和数字资产的交集中。

The Rise of HYPE: A Crypto Darling

炒作的兴起：加密货币亲爱的

HYPE has rapidly gained traction in the crypto market, reaching an all-time high of nearly $43 as of June 11, 2025. Launched in late November 2024, HYPE experienced an initial surge followed by a correction, but it has since rebounded strongly. As of June 2025, HYPE is the 12th-largest cryptocurrency by market capitalization. Hyperliquid, the blockchain behind HYPE, is designed to enhance DeFi applications, boasting a TVL of $1.7 billion, surpassing established platforms like Avalanche and Polygon.

Hype在加密货币市场上迅速获得了吸引力，截至2025年6月11日，历史最高近43美元。于2024年11月下旬推出，Hype经历了最初的激增，随后进行了更正，但此后的反弹很强。截至2025年6月，炒作是市值的第12大加密货币。 Hypliquid是炒作背后的区块链，旨在增强Defi应用程序，拥有17亿美元的TVL，超过了雪崩和Polygon等已建立的平台。

Strategic Advisor and Ecosystem Support

战略顾问和生态系统支持

To bolster its digital asset strategy, Eyenovia has appointed Max Fiege as Strategic Advisor. Fiege will focus on stakeholder education, ecosystem advocacy, treasury architecture, and risk oversight. His expertise in blockchain growth and crypto investments is expected to be invaluable in navigating the digital finance landscape and maximizing the value of Eyenovia's HYPE treasury.

为了加强其数字资产战略，Eyenovia任命了Max Fiege为战略顾问。 Fiege将专注于利益相关者教育，生态系统倡导，国库建筑和风险监督。他在区块链增长和加密投资方面的专业知识预计在浏览数字金融景观并最大程度地提高了Eyenovia炒作国库的价值方面是无价的。

Challenges and Opportunities Ahead

挑战和机遇

Despite the promising developments, Eyenovia faces challenges. The company is navigating a potential Nasdaq delisting due to an equity shortfall and is working on a compliance strategy. However, analysts project a significant revenue growth of 65.92% for the current fiscal year. Eyenovia continues to develop its Optejet User Filled Device (UFD), with FDA registration expected by September 2025, demonstrating its commitment to pharmaceutical innovation alongside its digital asset ventures.

尽管有前途的发展，但Eyenovia仍面临挑战。由于股权短缺，该公司正在潜在的纳斯达克脱颖而出，并正在制定合规策略。但是，分析师在本财政年度预计，收入的显着增长为65.92％。 Eyenovia继续开发其OPTEJET用户填充设备（UFD），FDA注册预计于2025年9月，证明了其对药品创新的承诺以及其数字资产风险投资。

Final Thoughts: A Risky But Potentially Rewarding Path

最终想法：冒险但有可能有所回报的道路

Eyenovia's journey is a fascinating blend of traditional pharmaceutical development and cutting-edge cryptocurrency strategy. While the path is fraught with risks, the potential rewards could be substantial. Whether Eyenovia can successfully navigate these challenges and capitalize on its unique position remains to be seen. One thing is for sure: it's a wild ride, and we're all here for it!

Eyenovia的旅程是传统制药开发和尖端加密货币策略的有趣融合。尽管这条道路充满了风险，但潜在的奖励可能是可观的。 Eyenovia是否可以成功应对这些挑战并利用其独特的立场还有待观察。可以肯定的是：这是一个疯狂的旅程，我们都在这里！